ArticleCancers2026
Small Is Beautiful: Is ctDNA Ready for Routine Implementation in Cancer Management?
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor DNA (ctDNA) has emerged as a transformative tool in cancer diagnostics, enabling the non-invasive detection of tumor-derived DNA fragments released into the bloodstream through cellular lysis or active secretion. ctDNA measurement has demonstrated its clinical usefulness, including early cancer detection, identification of resistance mechanisms, and screening of asymptomatic individuals. In addition to prognosis, ctDNA analysis is increasingly used to guide adaptive treatment strategies by detecting minimal residual disease and tracking tumor evolution in real time. Recent advances in artificial intelligence are poised to further enhance the clinical impact of ctDNA, transforming it from a passive monitoring biomarker into a dynamic molecular sensor integrated into predictive clinical decision models. However, broad implementation of ctDNA-based assays in routine practice requires rigorous prospective validation, cross-platform standardization, and regulatory approval to unlock its full potential in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.